[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]  Adam Feuerstein ✡️ [@adamfeuerstein](/creator/twitter/adamfeuerstein) on x 119.4K followers Created: 2025-07-09 11:24:11 UTC Merck $MRK to buy lung-disease biotech Verona Pharma $VRNA for $XX billion -- $XXX / share, XX% premium -- Deal centerpiece: Verona's Ohtuvayre, a treatment for chronic obstructive pulmonary disease. Blockbuster in the making. -- Merck needs to replace the expected loss of revenue when blockbuster cancer drug Keytruda loses patent protection. -- 2nd largest M&A transaction this year. -- Pharma has appetite for commercial-stage companies: Verona, Intra-Cellular, Blueprint XXXXXX engagements  **Related Topics** [$vrna](/topic/$vrna) [$mrk](/topic/$mrk) [stocks healthcare](/topic/stocks-healthcare) [Post Link](https://x.com/adamfeuerstein/status/1942907633389703229)
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
Adam Feuerstein ✡️ @adamfeuerstein on x 119.4K followers
Created: 2025-07-09 11:24:11 UTC
Merck $MRK to buy lung-disease biotech Verona Pharma $VRNA for $XX billion
-- $XXX / share, XX% premium -- Deal centerpiece: Verona's Ohtuvayre, a treatment for chronic obstructive pulmonary disease. Blockbuster in the making. -- Merck needs to replace the expected loss of revenue when blockbuster cancer drug Keytruda loses patent protection. -- 2nd largest M&A transaction this year. -- Pharma has appetite for commercial-stage companies: Verona, Intra-Cellular, Blueprint
XXXXXX engagements
Related Topics $vrna $mrk stocks healthcare
/post/tweet::1942907633389703229